Blood Test Predicts Onset of Alzheimer's Disease
|
By LabMedica International staff writers Posted on 22 Jul 2014 |
|
Image: The Luminex 200 System for Multiplex Testing (Photo courtesy of the University of Utah).
A combination of 10 proteins could predict whether individuals would progress from mild cognitive impairment to Alzheimer's disease (AD) within a year has been discovered.
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
All-in-One Molecular System
AIO M160
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Latest Clinical Chem. News
- Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
- Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
- Blood-Based Score May Support Targeted Interventions for Healthier Aging
- Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury
- Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
- Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
- Common Kidney Function Tests May Miss CKD in Cancer Patients
- Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
- Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
- Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
- Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
- Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
- Study Links Saliva-Based Epigenetic Signals to OCD Treatment Outcomes
- New One-Step Syphilis Test Could Enable Earlier Detection and Faster Treatment
- Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
- Study Evaluates Alzheimer’s Blood Biomarker Across Racial and Ethnic Groups
Channels
Molecular Diagnostics
view channel
AI-Supported Approach May Improve Cervical Cancer Screening in Low-Resource Settings
Cervical cancer screening coverage often remains below 15% in low- and middle-income countries. Limited accuracy of visual inspection with acetic acid, together with uneven access to high-quality human... Read more
Molecular AI Model Refines Risk Prediction in Pediatric Brain Tumors
Choosing treatment for a child with a malignant brain tumor requires balancing cancer control against lasting effects on learning, development, and quality of life. This balance is complicated by differences... Read more
Hematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
Immunology
view channel
Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Microbiology
view channel
Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more
Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more
Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Technology
view channel
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read more
Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
PCR amplifies DNA to enable highly accurate testing, but its reliance on complex, expensive laboratory analyzers has traditionally kept many workflows in centralized settings. A new personal DNA analyzer... Read more
Industry
view channel
Illumina Selected to Support National Genomics Study for Personalized Healthcare in Singapore
Singapore’s National Precision Medicine program is using genomic and health data to support more preventive and personalized healthcare. Its latest phase expands beyond healthy volunteers to people with... Read more
